Antibodies for Molecular Imaging of Cancer
暂无分享,去创建一个
Anna M Wu | A. Wu | Tove Olafsen | T. Olafsen
[1] S. Stoeckli,et al. Immunoscintigraphy of patients with head and neck carcinomas, with an anti-angiogenetic antibody fragment , 2007, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[2] M. Zalutsky. Potential of Immuno–Positron Emission Tomography for Tumor Imaging and Immunotherapy Planning , 2006, Clinical Cancer Research.
[3] J. Humm,et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. , 2007, The Lancet. Oncology.
[4] G. V. von Schulthess,et al. Radioimmuno positron emission tomography with monoclonal antibodies: A new approach to quantifying in vivo tumour concentration and biodistribution for radioimmunotherapy , 1991, Nuclear medicine communications.
[5] T Jones,et al. Quantitative measurement of monoclonal antibody distribution and blood flow using positron emission tomography and 124iodine in patients with breast cancer , 1991, International journal of cancer.
[6] N. Sneige,et al. Comparison of HER‐2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma , 2005, Cancer.
[7] M. Zöller,et al. Multistep tumor targeting in nude mice using bispecific antibodies and a gallium chelate suitable for immunoscintigraphy with positron emission tomography. , 1995, Cancer research.
[8] A. Wu,et al. Designer genes: recombinant antibody fragments for biological imaging. , 2000, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[9] S. Larson,et al. Single chain antigen binding protein (sFv CC49) , 1997, Cancer.
[10] A. Becker,et al. Trastuzumab and breast cancer. , 2001, The New England journal of medicine.
[11] C. Dence,et al. Antibody fragments labeled with fluorine-18 and gallium-68: in vivo comparison with indium-111 and iodine-125-labeled fragments. , 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[12] G. Adams,et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. , 1998, British Journal of Cancer.
[13] P. Garg,et al. PET imaging of osteosarcoma in dogs using a fluorine-18-labeled monoclonal antibody Fab fragment. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] Sanjiv S Gambhir,et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. , 2005, Cancer research.
[15] L. Adler,et al. Quantitation of small-animal (124)I activity distributions using a clinical PET/CT scanner. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] Sanjiv S. Gambhir,et al. Dual-Function Probe for PET and Near-Infrared Fluorescence Imaging of Tumor Vasculature , 2007, Journal of Nuclear Medicine.
[17] E. D. de Vries,et al. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. , 2007, European journal of cancer.
[18] N. Volkow,et al. PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[19] R. Hosse,et al. In vitro display technologies reveal novel biopharmaceutics , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[20] H. Bensadoun,et al. Efficiency of [18F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[21] Dario Neri,et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] E. Patzelt,et al. Gallium-68 chelate imaging of human colon carcinoma xenografts pretargeted with bispecific anti-CD44V6/anti-gallium chelate antibodies. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[23] D. Larsimont,et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] M. Welch,et al. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] S. Larson,et al. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] W. Mcbride,et al. Bispecific Antibody Pretargeting of Radionuclides for Immuno–Single-Photon Emission Computed Tomography and Immuno–Positron Emission Tomography Molecular Imaging: An Update , 2007, Clinical Cancer Research.
[27] H. Hoogenboom,et al. Selecting and screening recombinant antibody libraries , 2005, Nature Biotechnology.
[28] T. Powles,et al. Does PET imaging have a role in renal cancers after all? , 2007, The Lancet. Oncology.
[29] W. McBride,et al. Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] C. Anderson,et al. Copper chelation chemistry and its role in copper radiopharmaceuticals. , 2007, Current pharmaceutical design.
[31] L. Zardi,et al. Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectin , 2002, International journal of cancer.
[32] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[33] H. Lundqvist,et al. Pharmacokinetics and experimental PET imaging of a bromine-76-labeled monoclonal anti-CEA antibody. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[34] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] B. Davidson,et al. Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] C. Gillett,et al. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. , 1994, British Journal of Cancer.
[37] S. Gambhir,et al. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[38] R. Boellaard,et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. , 2003, Cancer biotherapy & radiopharmaceuticals.
[39] M J Welch,et al. RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[40] Sanjiv S Gambhir,et al. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[41] N. Lonberg,et al. Human Monoclonal Antibodies from Transgenic Mice , 2008, Handbook of experimental pharmacology.
[42] Jamal Zweit,et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. , 2002, Journal of the National Cancer Institute.
[43] A. Magener,et al. Immunoscintigraphy with positron emission tomography: gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies. , 2001, Cancer research.
[44] E. Eisenhauer. From the molecule to the clinic--inhibiting HER2 to treat breast cancer. , 2001, The New England journal of medicine.
[45] M. Welch,et al. Small-Animal PET of Tumor Angiogenesis Using a 76Br-Labeled Human Recombinant Antibody Fragment to the ED-B Domain of Fibronectin , 2007, Journal of Nuclear Medicine.
[46] J. Zidan,et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease , 2005, British Journal of Cancer.
[47] Paul J Yazaki,et al. Pilot Trial Evaluating an 123I-Labeled 80-Kilodalton Engineered Anticarcinoembryonic Antigen Antibody Fragment (cT84.66 Minibody) in Patients with Colorectal Cancer , 2004, Clinical Cancer Research.
[48] M J Welch,et al. Copper-64-labeled antibodies for PET imaging. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[49] G. Bakale,et al. Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. , 2007, Seminars in nuclear medicine.
[50] W. Mcbride,et al. Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting , 2007, Journal of Nuclear Medicine.
[51] Anna M Wu,et al. Arming antibodies: prospects and challenges for immunoconjugates , 2005, Nature Biotechnology.
[52] R. Boellaard,et al. Performance of Immuno–Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer Patients , 2006, Clinical Cancer Research.
[53] Fluorine-18 labeling of monoclonal antibodies and fragments with preservation of immunoreactivity. , 1991, Bioconjugate chemistry.
[54] H. Sasser,et al. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. , 2004, The Journal of urology.
[55] S. Larson,et al. Advances in positron emission tomography applications for urologic cancers , 2008, Current opinion in urology.
[56] R. Hawkins,et al. Clinical evidence of efficient tumor targetting based on single–chain Fv antibody selected from a combinatorial library , 1996, Nature Medicine.
[57] S. Larson,et al. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[58] R. Reilly,et al. Pretargeted tumour imaging with streptavidin immunoconjugates of monoclonal antibody CC49 and 111In-DTPA-biocytin. , 1996, Nuclear medicine and biology.
[59] S. Vallabhajosula,et al. Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model. , 2008, Radiology.